ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 105 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $20,060,000 | -35.1% | 1,000,000 | -8.7% | 0.24% | -35.8% |
Q2 2023 | $30,889,217 | -17.1% | 1,094,974 | -49.4% | 0.37% | -27.8% |
Q1 2023 | $37,247,477 | +1162.2% | 2,165,551 | +1378.0% | 0.51% | +1200.0% |
Q4 2022 | $2,950,893 | -57.4% | 146,519 | -54.2% | 0.04% | -59.8% |
Q3 2022 | $6,926,000 | +36.0% | 319,747 | +76.4% | 0.10% | +24.4% |
Q2 2022 | $5,094,000 | +171.0% | 181,272 | +344.9% | 0.08% | +151.6% |
Q1 2022 | $1,880,000 | -93.9% | 40,748 | -88.9% | 0.03% | -93.0% |
Q4 2021 | $30,949,000 | -8.6% | 368,173 | -27.5% | 0.44% | -19.9% |
Q3 2021 | $33,843,000 | +25.8% | 507,847 | +0.4% | 0.55% | +10.2% |
Q2 2021 | $26,902,000 | +330.1% | 505,675 | +250.8% | 0.50% | +261.2% |
Q1 2021 | $6,255,000 | -14.0% | 144,161 | +3.0% | 0.14% | -28.0% |
Q4 2020 | $7,272,000 | +61.3% | 140,000 | +1.5% | 0.19% | +30.4% |
Q3 2020 | $4,507,000 | +114.6% | 137,884 | +215.3% | 0.15% | +78.3% |
Q2 2020 | $2,100,000 | – | 43,726 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |